Home  Media Press releases 2005
|
|
|
| 28 July 2005 | 2005-07-28T01:00:00.0000000+01:00 |
|
ASTRAZENECA PLC
The Board of AstraZeneca PLC announces the appointment of David R Brennan as Chief Executive with effect from 1 January 2006 upon the retirement at that time of Sir Tom McKillop.
|
David Brennan is an Executive Director of AstraZeneca PLC and Executive Vice President, North America, responsible for the company’s business in the US and Canada.
Louis Schweitzer, Chairman of AstraZeneca PLC, said: “The Board’s appointment of David Brennan is the outcome of a rigorous selection process from a very strong list of candidates. David has over 30 years’ experience in the pharmaceutical industry and has played an important part in the development of AstraZeneca. With his fine leadership qualities and a strong and talented management team, the Board is confident that the company will continue to prosper”.
Media Enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033
Investor Enquiries:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Ed Seage, Tel: +1 302 886 4065
Jorgen Winroth, Tel + 1 212 579 0506
Biographical Details David R. Brennan, Executive Director, AstraZeneca PLC.
Member of the Executive Board of the Pharmaceutical Research and Manufacturers of America (PhRMA). Chairman of the Board of the Southeastern Chapter of the American Heart Association. General Manager of Chibret International, France (a subsidiary of Merck & Co., Inc.) 1990-1992. Vice-President of Marketing, Business Planning and Development Astra Merck, Inc., and then Astra Pharmaceuticals LP 1992-1999. Senior Vice-President of Commercial Operations AstraZeneca Pharmaceuticals LP 1999-2001. Executive Vice-President, North America, AstraZeneca PLC since 2001.
|
|
|